<?xml version="1.0"?>
<template xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="openEHR/v1/Template">
  <id>c3903240-c4f6-40a8-ab97-19d8897c3246</id>
  <name>COVID Tocilizumab Adult Order Group</name>
  <description>
    <lifecycle_state>Initial</lifecycle_state>
    <details>
      <purpose/>
      <use/>
      <misuse/>
    </details>
    <other_details>
      <item>
        <key>MetaDataSet:Sample Set </key>
        <value>Template metadata sample set </value>
      </item>
      <item>
        <key>Acknowledgements</key>
        <value/>
      </item>
      <item>
        <key>Business Process Level</key>
        <value/>
      </item>
      <item>
        <key>Care setting</key>
        <value/>
      </item>
      <item>
        <key>Client group</key>
        <value/>
      </item>
      <item>
        <key>Clinical Record Element</key>
        <value/>
      </item>
      <item>
        <key>Copyright</key>
        <value/>
      </item>
      <item>
        <key>Issues</key>
        <value/>
      </item>
      <item>
        <key>Owner</key>
        <value/>
      </item>
      <item>
        <key>Sign off</key>
        <value/>
      </item>
      <item>
        <key>Speciality</key>
        <value/>
      </item>
      <item>
        <key>User roles</key>
        <value/>
      </item>
    </other_details>
  </description>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]">
    <items>
      <item>
        <key>Transform.Technical Notes</key>
        <value>&lt;p&gt;OSQ #&amp;nbsp;440328&lt;/p&gt;</value>
      </item>
      <item>
        <key>Technical.ï»© Technical Traceability</key>
        <value>{~AHSID~c3903240-c4f6-40a8-ab97-19d8897c3246~NAME~COVID Tocilizumab Adult Order Group}</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.clinical_guidance.v1]">
    <items>
      <item>
        <key>Transform.Technical Notes</key>
        <value>&lt;p&gt;Sept 2/21 - Guidance text revision pending author approval&lt;/p&gt;</value>
      </item>
      <item>
        <key>CKT.Clinical Guidance</key>
        <value>&lt;p&gt;&lt;s&gt;Tocilizumab is recommended for severely ill patients requiring supplemental oxygen:&lt;br&gt;- if admitted to hospital for COVID-19 pneumonia 7 or fewer days ago OR;&lt;br&gt;- if they developed symptoms due to hospital acquired COVID-19 7 or fewer days ago OR;&lt;br&gt;- if they require supplemental oxygen to achieve a minimum SpO2 of 90% in the form of heated high-flow oxygen with FiO2 greater than 0.5, nasal prong delivered oxygen at a rate of 6 L/minute or more, or mask-delivered oxygen with FiO2 greater than 0.5, or they require non-invasive ventilation.&amp;nbsp;&lt;br&gt;&amp;nbsp;&lt;br&gt;Weight based dosing guidance:&lt;br&gt;Less than 40 kg: 8 mg/kg/dose&lt;br&gt;Greater than 40 kg to less than 65 kg: 400 mg&lt;br&gt;Greater than 65 kg to less than 90 kg: 600 mg&lt;br&gt;Greater than 90 kg: 800 mg&lt;/s&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;For the treatment of severe COVID-19 pneumonia, Tocilizumab is restricted as follows:&lt;/p&gt;&lt;p&gt;1.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Patient was admitted to hospital due to COVID-19 seven or fewer days ago &lt;strong&gt;OR&lt;/strong&gt; patient developed symptoms due to hospital-acquired COVID-19, while in hospital for other reasons, seven or fewer days ago&lt;/p&gt;&lt;p&gt;&lt;strong&gt;AND&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;2.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; The patient is experiencing significant respiratory failure, due to COVID-19 pneumonia, which requires:&lt;/p&gt;&lt;p&gt;a.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Invasive or non-invasive ventilation (e.g. Continuous Positive Airway Pressure or Bilevel Positive Airway Pressure) &lt;strong&gt;OR&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;b.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Supplemental oxygen to achieve a minimal SpO2 of 90%, in the form of one of the following:&lt;/p&gt;&lt;p&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; i.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Heated high flow oxygen with FiO2 &amp;gt; 0.5 (e.g. Optiflow, Airvo)&lt;/p&gt;&lt;p&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; ii.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Oxygen delivered via nasal prong at a rate &amp;gt; 6 L/minute&lt;/p&gt;&lt;p&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; iii.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Mask delivered oxygen with FiO2 &amp;gt; 0.5 (e.g. non-rebreather or Venturi mask)&lt;/p&gt;&lt;p&gt;&lt;strong&gt;AND&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;3.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; No more than 24 hours has elapsed since initiation of ventilation as defined above or since the patient met the oxygen thresholds stated above&lt;/p&gt;&lt;p&gt;&lt;strong&gt;AND&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;4.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; The patient has not received another dose of tocilizumab for the same indication at any point during their current hospitalization. The use of tocilizumab as above is restricted to a SINGLE DOSE per patient, based on the following weight-based dosing:&lt;/p&gt;&lt;p&gt;40 or less kg: 8 mg/kg&lt;/p&gt;&lt;p&gt;Greater than 40 kg to 65 or less kg: 400 mg&lt;/p&gt;&lt;p&gt;Greater than 65 kg to 90 or less kg: 600 mg&lt;/p&gt;&lt;p&gt;Greater than 90 kg: 800 mg&lt;/p&gt;&lt;p&gt;For clinicians not familiar with the use of tocilizumab, specialist consultation (e.g., internal medicine, infectious disease, critical care) is recommended prior to starting therapy.&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-INSTRUCTION.section_supporting_context.v1]">
    <items>
      <item>
        <key>Transform.Preselected</key>
        <value>&lt;p&gt;N&lt;/p&gt;</value>
      </item>
    </items>
  </annotations>
  <definition xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" name="tocilizumab">
    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" path="/items"/>
    <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="02090773-b839-4322-9faf-55959041c9c7" concept_name="PHARM tocilizumab injection Order" max="1" path="/items" name="tocilizumab injection; *** mg, intravenous, once"/>
    <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items"/>
  </definition>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.adhoc.v1">
    <digest id="MD5-CAM-1.0.1">8AE70853975A75254E6D39A8DE3652AF</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1">
    <digest id="MD5-CAM-1.0.1">4B2F0F6CD593E442DA9C30277A3EA9CF</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1">
    <digest id="MD5-CAM-1.0.1">AD8DFB192E67715F0D9E11E95E674AD0</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.service_request_information.v1">
    <digest id="MD5-CAM-1.0.1">230A8D964017E1FD7AC82EBDEE0202A6</digest>
  </integrity_checks>
  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1">
    <digest id="MD5-CAM-1.0.1">A7EC4E4C870D8C3431B29F6514353416</digest>
  </integrity_checks>
</template>